Citigroup Maintains Buy on Nektar Therapeutics, Raises Price Target to $151
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Samantha Semenkow maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price target from $123 to $151.
Citigroup analyst Samantha Semenkow maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price target from $123 to $151.